ArticleThe international journal of cardiovascular imaging2026
Evaluation of the diagnostic value of dual-time-point, multi-parameter 99mTc-PYP imaging in diagnosing Transthyretin Cardiac Amyloidosis.
Article in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective To assess the clinical value of dual-time-point planar imaging and SPECT/CT tomographic imaging of 99mTc-PYP in diagnosing transthyretin cardiac amyloidosis (ATTR-CA), and to compare the diagnostic performance of different imaging time points and methods. Methods A retrospective analysis of 98 suspected CA patients (ATTR-CA 12; AL-CA 23; non-CA 63). Early imaging at 1 h and delayed imaging at 3 h included planar and tomographic imaging. Evaluations used the Perugini visual grading, heart-to-contralateral lung uptake ratio (H/CL), and tomographic semi-quantitative scoring. Pathology biopsy and genetic testing served as the gold standard. Sensitivity, specificity, and accuracy were compared across methods. Results Delayed tomographic imaging for ATTR-CA achieved a sensitivity of 100.0%, specificity of 96.5%, and accuracy of 96.9%, the best among all methods. The earliest Perugini scoring method had the lowest accuracy (80.6%), and early imaging using the H/CL method had the lowest diagnostic sensitivity (58.3%). SPECT/CT imaging at 3 h provides significant incremental diagnostic value compared to planar imaging and offers the greatest benefits, Cases that were missed during the initial review have been reclassified.Delayed imaging was superior to early imaging overall, and tomographic imaging significantly reduced false positives caused by blood-pool artifacts. Conclusion Dual-time-point 99mTc-PYP imaging with tomographic imaging can significantly improve the diagnostic accuracy for ATTR-CA, with delayed SPECT/CT performing best. For cases with atypical early imaging or diagnostic difficulty due to blood-pool tracer distribution, when Perugini grade is 2, early H/CL ≤ 1.5 or delayed H/CL ≤ 1.3, or in highly suspected cases where early imaging provides insufficient diagnostic evidence, routine inclusion of delayed SPECT/CT in the imaging workflow for suspected ATTR-CA is recommended to optimize subtyping and guide subsequent therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.